Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pregnenolone for Menopausal and Perimenopausal Depression
NCT03505905Phase 2Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- Sep 2018
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pregnenolone in major depressive disorder (MDD) (4 arms), sponsored by UT Southwestern Medical Center. Primary endpoint: Montgomery-Asberg Depression Rating Scale at Week 16. Started Sep 2018; status: completed.
02
Drugs
pregnenolone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03505905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03505905.